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Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with
chronic uremia. Controversy exists as to whether 24,25(OH)2D3 has a
direct inhibitory effect on parathyroid hormone (PTH) secretion. There-
fore, the present investigation examined the effect of long-term admin-
istration of 24,25(OH)2D3 on immunoassayable PTH levels (iPTH) and
bone histology in dogs with chronic renal failure. Chronic renal failure
was produced in 16 dogs, half of which served as controls whereas the
other half received 2.5 g/day of 24,25(OH)2D3, orally. Serum iPTH,
serum total, ionized calcium, serum phosphorus, and creatinine were
followed at weekly or biweekly intervals in both groups. Also, cre-
atinine clearances, serum levels of 25(OH)D3, 24,25(OH)2D3, and
I ,25(OD)2D3 and the intestinal absorption of calcium were measured.
After 1 year of chronic renal failure the dogs were sacrificed and rib
biopsy specimens were obtained for histological examination and
measurement of mineral content. Serum iPTH increased equally in the
two dog groups with no effect at any time of 24,25(OH)2D3 treatment,
despite a significant increase in the serum levels of 24,25(OH)2D3 and a
concomitant decrease of the 1,25(OH)2D3 levels. There was no differ-
ence in the levels of serum calcium or in the calcium content of bone.
Furthermore, after 8 months of uremia three control dogs were
switched to the group treated with 24,25(OH),D3 and followed for
another 7 months. No suppressive effect of administering 24,25(OH),D3
on the iPTH levels could be demonstrated in these three dogs. On the
rib biopsy specimens the number of osteoclasts was increased in the
24,25(OH)2D3-treated dogs, compared to control uremic dogs and
normal control dogs, indicating no inhibition by 24,25(OH)2D3 of the
effect of PTH on bone. tt is concluded that long-term treatment with
24,25(OH)2D3 alone in dogs with chronic renal failure has no effect
either on the secretion or on the skeletal effects of PTH.
Effet de Ia 24,25(OH)2D3 sur les niveaux de PTH et l'histologie osseuse
chez des chiens en urémie chronique. II existe une controverse quant a
un effet inhibiteur direct de la 24,25(OH)2D3 sur la sdcrdtion d'hormone
parathyroIdienne (PTH). C'est pourquoi cette étude a examine l'effet de
l'administration a long ter.ie de 24,25(OH)2D3 sur les niveaux de PTH
dosables immunologiquement (iPTH) et sur l'histologie osseuse de
chiens avec insuffisance rénale chronique. L'insuffisance rénale
chronique a été provoquée chez 16 chiens, dont Ia moitié servait de
contrOles, tandis que I'autre moitié a recu 2,5 g par jour de
24,25(OH)2D3 orallement. L'iPTH sdrique, Ia calcémie totale et ionisée,
Ia phosphorémie et Ia créatininémie ont été suivies a intervalles
hebdomadaires ou bihebdomadaires dans les deux groupes. En plus, les
clearances de Ia créatinine, lex niveaux sériques de 25(OH)D3, de
24,25(OH)D3, de 24,25(OH)2D, et de 1,25(OH)2D1 et l'absorption
intestinale du calcium ont été mesurées. Aprês I an d'insuffisance
rénale chronique, les chiens ont éé sacriflés et des specimens biopsies
costales ont éíé obtenues pour examen histologique et mesure du
contenu mineral. L'iPTH sérique a augmenté egalement dans les deux
groupes de chiens sans effet a aucun moment du traitement par Ia
24,25(OH)2D3, malgré une augmentation significative des niveaux
sériques de 24,25(OH),D3 et une baisse concomitante des niveaux de
1,25(OH)2D3. Ii n'y avait pas de difference entre les niveaux de
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calcémie ou le contenu calci que de l'os. En outre, trois chiens
contrôles ant été transférés au bout de 8 mois d'urémie, au groupe traité
avec la 24,25(OH)2D3 et suivis encore 7 mois. Aucun effet suppresseur
de l'administration de 24,25(OH)2D3 sur les niveaux d'iPTH n'a pa étre
dCmontré chez ces trois chiens. Sur les specimens biopsies costales, le
nombre d'ostéoclastes était accru chez les chiens traités avec Ia
24,25(OH)2D3, par rapport aux chiens contrôles urémiques et aux
chiens contrOles normaux, ce qui indique l'absence d'inhibition par Ia
24,25(OH)2D3 de l'effet de la PTH sur l'os. On conclut que le traitement
a long terme par Ia 24,25(OH)2D3 seule chez des chiens en insuffisance
rdnale chronique n'a d'effet ni sur la sécrétion ni sur les effets
squelettiques de PTH.
A potential interrelationship between parathyroid glands and
vitamin D metabolites may play a key role in the homeostasis of
calcium in humans. Since parathyroid hormone (PTH) controls
the production of 1,25(OH)2D3 via activation of the
1-hydroxylase, l,25(OH)2D3 or other vitamin D metabolites
might in turn act directly on the parathyroid glands to inhibit
PTH secretion. Divergent results have been published regard-
ing a direct effect of l,25(OH)2D3 on PTH secretion. It has been
reported that 1,25(OH)2D3 inhibits [1, 21, stimulates [31, or has
no effect on PTH secretion [41.
The 24,25(OH)2D3 metabolite is less active than l,25(OH)2D3
[5, 61. Recently, it has been postulated that 24,25(OH)2D3
directly inhibits the secretion of PTH. Care et al [7] have
demonstrated a fall in PTH secretion in goats infused with
24,25(OH)2D3. Also, Canterbury et al [3] have shown that the
infusion of 24,25(OH)2D3 into the thyroid artery of normal dogs
resulted in a rapid suppression of PTH release. Subsequently,
the same investigators [81 examined the effect of administering
2 pg/day of 24,25(OH)2D3 to dogs with chronic renal failure.
The effect was a 40 to 60% decrease in immunoreactive PTH
levels. However, other investigators have failed to demonstrate
a suppressive effect of 24,25(OH)2D3 on the release of PTH.
Studies by Tanaka et al [9] in vitamin D-deficient and vitamin
D-supplemented rats indicated that serum parathyroid hormone
(i-PTH) levels did not change in response to 24,25(OH)2D3.
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Henry, Taylor, and Norman [101 demonstrated that
24,25(OH)2D3 alone had no effect on parathyroid glands of
chicken and similar negative results were observed using cul-
tures of rat parathyroid gland [11]. Dietel et al [121 found no
effect of 24,25(OH)2D3 on normal porcine parathyroid glands
and human parathyroid adenomas maintained in a culture
system. Our laboratory studies [131 with isolated dispersed
bovine and canine parathyroid cells failed to show any effect of
24,25(OH)2D3 on the secretion of PTH.
In view of the divergent results published in the literature we
have carefully examined the effect of 24,25(OH)2D3 on the
release of PTH in uremic dogs and on the bone disease which
accompanies long-term uremia.
Methods
Renal insufficiency was produced in twenty adult mongrel
female dogs (weighing 17.2 2.3 kg [SD]) by ligation of most of
the branches of the left renal artery followed by contralateral
nephrectomy 1 week later. Before the dogs were included in the
investigation, it was confirmed that all had normal kidney
function, normal iPTH levels, normal serum phosphate, ionized
calcium, and total calcium. Three to four weeks after chronic
renal failure (CRF) was introduced, creatinine clearances were
measured and the 20 dogs were divided into two groups, each
having a similar degree of reduced kidney function. Within the
first 3 months after uremia was induced in the dogs, four died—
two in each group. The remaining 16 uremic dogs survived for
at least another 12 months. One month after the operation
treatment with 24,25(OH)2D3, 2.5 rg/day administered orally,
was begun in one group of eight dogs. The other eight dogs
served as a control group. After 8 months of chronic renal
failure three of the dogs from the uremic control group were
treated with 24,25(OH)2D3 and remained on this treatment for
another 7 months. All uremic dogs received normal dog chow
containing 1.6% of calcium and 1.1% of phosphorus. All dogs
had free access to water.
The following parameters were measured on each dog every
week for 12 to 15 months: total serum calcium, ionized calcium,
phosphorus, creatinine, sodium, potassium, and magnesium.
• Every second week serum iPTH (C-terminal assay) was
measured.
• Every 3 months creatinine clearance was measured.
• The serum levels of 25(OH)D, 24.25(OH)2D3, and
l,25(OH)2D3 were measured after 6 and 12 months of chronic
renal failure.
• Intestinal calcium absorption was measured after 6 months
of uremia.
• The dogs were sacrificed after 12 to 15 months of chronic
uremia and the calcium, phosphorus, and magnesium content of
bone specimens from the ribs were measured. Furthermore, at
the time of sacrifice rib biopsy specimens were obtained for
histological examination.
Serum iPTH was measured by a COOH-terminal assay using
the antibody CH9 [14]. Serum ionized calcium was measured by
the Orion SS-20 electrode [15]. Total serum calcium and mag-
nesium were measured by atomic absorption photometry. Se-
rum creatinine, phosphorus, sodium, and potassium were mea-
sured by an autoanalyzer. Creatinine clearances were estimated
by an exogenous creatinine infusion. Intestinal calcium absorp-
tion was measured by a simplified method previously described
[161.
25-Hydroxy vitamin D3 [25(OH)D3] was measured by a
competitive protein-binding assay [17], as were 24,25-
dihydroxyvitamin D1 [24,25(OH)2D31 [18, 19] and 1,25-
dihydroxyvitamin D3 [l,25(OH)2D3] [20].
The bone content of calcium, phosphorus, and magnesium
was determined after incineration of a completely dried rib
biopsy specimen, which was totally cleaned of fat and muscle.
The fat was extracted by a mixture of ethanol/chloroform (3:1),
and the bone was dried by air pressure and weighed (wet
weight). The sample was then dried in an oven at 100°C for 24
hr and weighed again (dry weight); afterwards it was placed in
a crucible oven at 600 to 700°C for 48 hr. Thereafter, 5 ml of
hydrochloric acid were added to the samples, and the ion
concentrations was determined by atomic absorption photom-
etry. The results were expressed in milligrams per gram of dry
weight of bone.
Bone histology was examined after approximately 1 year of
chronic uremia just before the two experimental groups were
sacrificed. Bone biopsy specimens were obtained from the 10th
rib of each dog. Non-decalcified histological sections were
prepared (5 to 10 .r thick) on a sledge microtome (Jung Model
K, Heidelberg, Germany) and histometrically quantitated as
previously described [211. The following parameters were mea-
sured: (1) percent of relative osteoid volume, or the percent of
bone matrix which was nonmineralized; (2) percent of total
osteoid surface, or the percent of trabecular surface covered by
non-mineralized matrix (osteoid); (3) osteoclast index, or the
number of osteoclasts/mm2 total bone area; (4) calcification
front formation, or the percent of osteoid seam-mineralized
bone interface with fluorescent tetracycline label; and (5) the
cellular rate of mineralization or the mean distance between
double fluorescent tetracycline labels divided by the interdose
duration. The tetracycline labelling was performed by adminis-
tering 1 g of tetracycline (500 mg every 12 hr) orally to the dogs
on days 1 and 2 and again on days 14 and 15. The biopsy
specimen was then obtained on day 18.
Results
The creatinine clearances in the two dog groups were equally
reduced after 3 weeks of uremia and remained stable after 1
year, with a mean value of 19 3.8 mI/mm in the uremic
control group and 16 3.1 mI/mm in the group treated with
24,25(OH)2D3. There was no significant difference in the levels
of alkaline phosphatase between the two groups. The intestinal
absorption of calcium (measured after 6 months of chronic
uremia) and expressed in fractional terms was 27% in the
24,25(OH)2D3-treated group and 22% in the control group.
However, these values were not significantly different from
each other. The fractional absorption of calcium in these
animals was not significantly different from the range of frac-
tional absorption observed in six normal dogs (18 to 38%). A
normal intestinal calcium absorption despite low plasma levels
of l,25(OH)2D3 may, however, indicate a biologic effect of
24,25(OH)7D3 in these 24,25(OH)7D3-treated dogs.
The serum levels of the different vitamin D metabolites after
1 year of uremia are depicted in Figure 1. The levels of
25(OH)D3 were not significantly different between the two
groups and were also not significantly different from the level
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Fig. 1. Levels of different vitamin D metabolites in plasma (tIter] year
of uremia in control dogs (•) and dogs treated () with 24,25(OH)2D.
Values for 25(OH)D3 were not significantly different from each other.
The levels of 24,25(OH), were significantly higher (P < 0.005) in the
dogs receiving this metabolite. The levels of I ,25(OH),D were signifi-
cantly lower (P < 0.02) in the treated group.
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Fig. 2. Mean serum levels of iPTH, ionized calcium, total calcium and
phosphorus in uremic control dogs (U) and uremic dogs treated ()
with 24,25(OH),D3 for 1 year. No significant differences were found
between the groups in any of these measurements.
observed in dogs with normal kidney function [32.8 1.4 ng/ml
(mean SE)].
The mean concentration of 24,25(OH)2D3 in serum was
significantly higher (P <. 0.005) in the dog group treated with
24,25(OH)2D3 (7.6 1.1 and 2.4 0.8 ng/rnl, respectively)
than in the uremic control dogs, but neither group was signifi-
cantly different from the levels of six control dogs with normal
kidney function (4.9 1.3 ng/ml). In contrast to the
24,25(OH)2D3 levels, the serum concentrations of 1 .25(OH)7D3
were significantly suppressed in the group of 24,25(OH)2D3-
treated dogs (P < 0.02) compared to the serum concentrations
in the uremic control group (13.3 2.7 against 32.9 5.5
pg/mI), but not significantly different compared to the level in
serum of six dogs with normal kidney function (31.6 13.7
pg/mi). However, this lack of a significantly difference was
probably due to the large variation in the normal levels.
Figure 2 depicts the mean concentrations of serum 1PTH,
serum ionized calcium, total calcium, and phosphorus in the
two uremic groups after 1 year of chronic renal failure. Com-
pared to the levels in dogs with normal kidney function (<60
jilEq/ml), the iPTH levels were significantly elevated (P <
0.001) in both uremic dog groups. However, there was no
significant difference between the two groups of uremic dogs,
whether or not they had been treated with 24,25(OH)2D3.
Neither the serum calcium nor phosphorus concentrations were
significantly different between the two uremic groups and only
the serum phosphorus differed (P < 0.05) from the one in
normal dogs (4.7 0.5 mg/dl).
Figure 3 illustrates the change in the levels of serum iPTH in
the two uremic dog groups during the first 8 months of chronic
renal failure. Also shown are the changes in the serum levels of
ionized calcium and creatinine. The rise in serum creatinine
occurred within the first month of uremia, thereafter the serum
creatinine levels remained stable and were not significantly
different between the two groups. The serum ionized calcium
showed a small increase in both groups shortly after the
reduction in renal mass and then remained stable and was not
different between the two groups. Thus, as depicted in Figure 3
no effect on long-term treatment with 24,25(OH)2D3 could be
demonstrated on the serum levels of iPTH in dogs with stable
kidney function and serum ionized calcium. In both uremic dog
groups the serum levels of iPTH increased from normal values
to values between 600 and 800 dEq/ml, without significant
differences between the two groups.
Three of the control (untreated) dogs with chronic renal
failure were administered 24,25(OH)2D1 after 8 months of
uremia and remained on this treatment for the following 7
months. After the initial 8 months of uremia, the serum cre-
atinine was 2 mg/dl in one dog and remained stable during the
next 7 months of treatment with 24,25(OH)2D3. The serum
creatinine concentrations were 4.1 and 4.2 mg/dl in the other
two dogs at the end of the control period (8 months) and
doubled during the next 7 months of treatment with
24,25(OH)2D. Total and ionized serum calcium levels were
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Fig. 3. Serum levels of iPTH, ionized calcium, and creatinine in control
uremic dogs (CRF) and in uremic dogs receiving 24,25(OH)2D3 [CRF +
24,25(OH)2D] ftr 8 months.
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Fig. 4. Serum iPTH levels in three dogs with chronic renal failure,
before (CRF) and during treatment with 24,25(OH)2D3 [CRF +
24,25(OH)2D3].
stable in the dog with a serum creatinine of 2 mg/dl, while the
ionized calcium concentration fell from 5.0 to 4.1 mgldl and 5.4
to 3.4 mg/dl in the two other dogs (total serum calcium fell from
12.2 to 10.7 and from 11.9 to 7.2 mg/dl, respectively). Despite
treatment with 24,25(OH)2D3 iPTH levels increased signifi-
cantly in all three dogs, demonstrating that treatment with
24,25(OH)2D3 did not inhibit the development of secondary
hyperparathyroidism in these three dogs with either progressive
chronic renal failure (two) or mild stable chronic renal failure
(one) (see Fig. 4).
As shown on Figure 5 treatment with 24,25(OH)2D3 did not
change the calcium content of bone when compared to that of
normal or uremic control dogs. However, the magnesium
content of bone was significantly increased (P < 0.001), in
comparison to both uremic and normal control dogs. Similarly,
the bone phosphorus content was slightly but significantly
higher (P < 0.05) in 24,25(OH)2D3-treated dogs than in uremic
control dogs, although both groups had a lower bone phospho-
rus content than normal control dogs.
The main results of the bone histology from the two uremic
groups of dogs are depicted in Figure 6. The osteoclast index
(the number of osteoclasts per mm2 per total bone area) was
significantly (P < 0.005) increased in the uremic control group,
compared with normal control dogs. However, the most strik-
ing finding was a further significant increase (P < 0.001) in the
osteoclast index of the uremic group treated with
24,25(OH)2D3. Thus, there was no histological evidence that
24,25(OH)2D3 ameliorated the skeletal consequences of the
secondary hyperparathyroidism of chronic renal failure. The
relative osteoid volume and the total osteoid surface (both in
percent) were both significantly increased in the two uremic
groups compared to normal control dogs, but not significantly
influenced by treatment with 24,25(OH)2D3. The cellular rate of
mineralization, which is a measure of the bone synthesizing
Fig. 5. Calcium, magnesium, and phosphorus content of the rib. The
mineral content of bone from normal dogs is compared with that of dogs
with chronic renal failure (CRF) and uremic dogs treated with
24,25(OH)2D3. There was no difference in calcium content, while the
magnesium content of ribs from uremic dogs treated with 24,25(OH)2D3
was significantly higher than that of uremic control dogs (P < 0.001).
Statistics between the two CRF groups are represented in the figure by
* P<0.O5and**,P<0.001.
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capacity of the average osteoblast, was normal in both control
uremic and 24,25(OH)2D3-treated dogs (Fig. 7). Similarly, cal-
cification front formation which reflects the proportion of
osteoid seam taking part in the mineralization process was
normal in both uremic dog groups (Fig. 8).
Discussion
The present investigation clearly demonstrates that long-term
treatment of uremic dogs with 24,25(OH)2D3 has no suppressive
effect on the serum levels of PTH, as detected by a COOH-
terminal PTH assay. Adequate intestinal absorption of
24,25(OH)2D3 was confirmed by the finding of significantly
higher levels of serum 24,25(OH)2D3 in the treated group as
compared to the uremic control group. This demonstration of a
lack of a suppressive effect of 24,25(OH)2D3 on the PTH levels
in serum agrees with the results of Tanaka et al [9] in the rat and
with those of Llach et al [22] in the uremic human. Similarly,
Henry, Taylor, and Norman [10] did not detect any effect of
24,25(OH)2D3 on the secretion of PTH or formation of cyclic
AMP from normal porcine parathyroid glands or human
parathyroid adenomas in organ culture. Finally, Kanis et al [23]
did not notice any change in PTH levels when giving
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Fig. 6. Bone histology of the ribs of normal dogs compared with the
histology qf ribs from dogs with chronic renal failure and of ribs from
dogs with chronic renal failure treated with 24,25(OH)2D3.
Effects of 24,25(OH)7D3 on PTH levels 795
24,25(OH)2D3 to patients with renal disease and secondary
hyperparathyroidism or to normal subjects.
However, other investigators have demonstrated a significant
inhibition of PTH secretion in the dog, which was independent
of changes in the serum ionized calcium after 24,25(OH),D3
administration. This occurred both within minutes after an
intravenous injection of 24,25(OH),D3 [3] and after oral admin-
istration of 24,25(OH)2D1 to uremic dogs [81. The reason for the
discrepancy between the results of the last-mentioned investi-
gation [81 and those of the present study remains to be clarified.
Both investigations were performed in dogs, the degree of
uremia was about the same, and the doses of 24,25(OH)2D3
were not significantly different. The amount of calcium in the
diet was also similar in both studies. The uremic dogs of
Canterbury et al [8] were treated with 24,25(OH)2D3 for 3 weeks
and an inhibitory effect on the PTH levels was already seen
after I week of treatment. In the present study the dogs were
treated with 24,25(OH)21)3 for approximately 1 year and at no
time during the course of the study could we demonstrate
inhibition of PTH secretion.
In rats with acute uremia Pavlovitch et al [241 found that
short-term administration of 24,25(OH)2D3 before bilateral
nephrectomy prevented the rise in serum iPTH, seen in a
control uremic group. Miravet et al [251 found a small, but not
significant, suppression of the serum iPTH levels in patients
with vitamin D-deficient osteomalacia. However, a more pro-
nounced suppression of the serum iPTH was demonstrated
during treatment with other vitamin D metabolites: 25(OH)D-4,
l,25(OH)2D3, 25,26(OH)7D3. Cloix et al [261 found that 24.
25(OH)2D3 inhibited the isoproterenol- and sodium fluoride-
stimulated adenylate cyclase activities in plasma membranes
obtained from parathyroid adenomas of patients with primary
hyperparathyroidism and from hyperplastic glands obtained
from patients with chronic renal failure. Finally, Christiansen et
al [27] suggested that a direct suppressive effect of
24,25(OH)2D3 on the parathyroid gland may exist in patients
with chronic renal failure. Thus, discrepancies exist regarding
the effect of short-term treatment with 24,25(OH)2D3 either in
vivo or in vitro on PTH secretion. However, the present
investigation has clearly demonstrated that during long-term
treatment (1 year) there was no inhibitory effect of
24,25(OH)2D3 on the secretion of PTH. Furthermore, in the
present investigation no effect was found on the levels of serum
ionized calcium, phosphorus, and magnesium, or the calcium or
phosphorus content of bones of uremic dogs. A small but
significant increase in the magnesium content of the bone was
found in the 24,25(OH)2D3-treated group. The significance of
this finding remains to be clarified.
Our histological observations also indicate that 24,25(OH),D3
does not ameliorate the skeletal consequences of hyperpara-
thyroidism. For example, the cellular rate of mineralization and
calcification front formation are unaffected by such treatment.
We have previously shown that the only uremic patients with
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Fig. 7. Cellular rate of mineralization as measured by the double
tetracycline labeling. The rate was not different from that of normal
dogs in either of the uremic groups.
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normal calcification front formation are those with the highest
circulating iPTH levels [28]. Furthermore, our 24,25(OH)7D3-
treated dogs have even more osteoclasts than do our control
uremic dogs. The genesis of the 24,25(OH),D3-induced
osteoclastogenesis is enigmatic but has been noted previously
1291. The lack of histological evidence of increased bone forma-
tion as determined by the percent of osteoid surface and
tetra ycline-based parameters indicates that the osteoclast pro-
liferation which occurred with 24,25(OH)2D3 treatment is not a
consequence of the remodelling process. Specifically, remodel-
ling is characterized by parallel changes in bone formation and
resorption, an event which did not occur in our 24,25(OH)7D1-
treated animals. 24,25(OH),D3 is capable of directly stimulating
resorption in bone organ culture at concentrations which ap-
proximate those achieved pharmacologically in our dogs [30].
Furthermore, vitamin D is known to act in concert with PTH to
promote osteoclastic activity [31], and the possibility remains
that 24,25(OFI)2D3 may exert such a synergistic effect, particu-
larly in a milieu of severe hyperparathyroidism.
No influence on any other histological parameter could be
demonstrated after treatment with 24,25(OH)2D3, which agrees
with the results of Muirhead et al [32] and Evans et al [33].
Howeve: high doses of 24,25(OH),D3 did ameliorate the bone
disease ( vitamin D-deficient rats in the study by Fuchs et al
[34] and may have a beneficial effect on the uremic bone disease
connected with high aluminum loads [35, 36].
In a recent investigation on the skeletal resistance to PTH in
chronic uremia, using the model of the isolated perfused canine
tibia, we found no effect of long-term treatment with
24,25(OH)2D3 on the diminished cyclic AMP response to stimu-
lation by PTH 1-34 [37]. This agrees with the results of
Lieberherr et al [38] in the rat calvaria, but in contrast to the
tesults of Marcus, Orner, and Brickman [39] in rat bone.
Thus, in dogs with chronic renal failure no effect of long-term
treatment with 24,25(OH)2D3 could be demonstrated on: (1) the
secretion of PTH (as measured by a COOH-terminal assay); (2)
the PTH-induced skeletal changes of chronic uremia (as mea-
sured by an increased number of osteoclasts); or (3) the skeletal
resistance to PTH 1-34 (as demonstrated by a reduced cyclic
AMP response to stimulation by PTH) [37].
Therefore, we conclude that long-term treatment with
24,25(OH)2D3, alone, in dogs with chronic renal failure has no
effect either on the secretion or on the skeletal effects of PTH.
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